前列腺癌患者激素治疗的副作用。
The side effects of hormonal therapy at the patients with prostate cancer.
作者信息
Ziółkowska Ewa, Zarzycka Małgorzata, Wiśniewski Tomasz, Zyromska Agnieszka
机构信息
Department of Radiotherapy I, Oncology Centre - prof. Franciszek Łukaszczyk Memorial Hospital, Bydgoszcz, Poland.
出版信息
Contemp Oncol (Pozn). 2012;16(6):491-7. doi: 10.5114/wo.2012.32478. Epub 2013 Jan 4.
Abstract
Prostate cancer is one of most frequent malignant tumours at men. The androgen-deprivation therapy is the part of cancer treatment. It could be used both in the early stage of prostate cancer and in the bone metastates. From this reason the antiandrogen drugs waste systematically grows. Unfortunately androgen-deprivation therapy has numerous side effects such as: the inferior quality of live, sexual disturbances, the fatigue, the anaemia, the bone mineral density loss and the increase of the risk of breaks the bone, the increase of body mass, insulinresistance, hypercholesterolemia, the increase risk of cardiac disorders. The aim of this article is the introduction of the reader with possibly complications androgen-deprivation therapy and with possibilities in diagnosis and treatment.
摘要
前列腺癌是男性中最常见的恶性肿瘤之一。雄激素剥夺疗法是癌症治疗的一部分。它可用于前列腺癌的早期阶段以及骨转移阶段。因此，抗雄激素药物的消耗量在系统性地增长。不幸的是，雄激素剥夺疗法有许多副作用，如生活质量下降、性功能障碍、疲劳、贫血、骨矿物质密度丧失和骨折风险增加、体重增加、胰岛素抵抗、高胆固醇血症、心脏疾病风险增加。本文的目的是向读者介绍雄激素剥夺疗法可能出现的并发症以及诊断和治疗的可能性。
相似文献
1
The side effects of hormonal therapy at the patients with prostate cancer.前列腺癌患者激素治疗的副作用。
Contemp Oncol (Pozn). 2012;16(6):491-7. doi: 10.5114/wo.2012.32478. Epub 2013 Jan 4.
2
Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.在接受雄激素剥夺治疗的局部晚期前列腺癌男性患者中管理骨质流失。
J Urol. 2008 Feb;179(2):414-23. doi: 10.1016/j.juro.2007.09.028.
3
Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.接受雄激素剥夺疗法治疗前列腺癌的男性中的骨质疏松症。
J Urol. 2002 May;167(5):1952-6.
4
The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients.长期雄激素剥夺治疗后局部前列腺癌患者骨密度变化的临床意义。
J Urol. 2021 Jun;205(6):1648-1654. doi: 10.1097/JU.0000000000001646. Epub 2021 Feb 12.
5
Complications of androgen-deprivation therapy for prostate cancer.前列腺癌雄激素剥夺治疗的并发症。
Clin Prostate Cancer. 2003 Dec;2(3):147-52. doi: 10.3816/cgc.2003.n.022.
6
The effect of androgen deprivation therapy on periodontal disease in men with prostate cancer.雄激素剥夺疗法对前列腺癌男性患者牙周疾病的影响。
J Urol. 2007 Mar;177(3):921-4. doi: 10.1016/j.juro.2006.10.067.
7
Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.在雄激素剥夺治疗的第一年开始使用唑来膦酸可增加前列腺癌患者的骨矿物质密度。
J Urol. 2006 Sep;176(3):972-8; discussion 978. doi: 10.1016/j.juro.2006.04.078.
8
Bone health in men receiving androgen deprivation therapy for prostate cancer.接受前列腺癌雄激素剥夺治疗的男性的骨骼健康
J Urol. 2007 Jan;177(1):17-24. doi: 10.1016/j.juro.2006.08.089.
9
Androgen deprivation therapy: evidence-based management of side effects.雄激素剥夺疗法：副作用的循证管理。
BJU Int. 2013 Apr;111(4):543-8. doi: 10.1111/j.1464-410X.2012.11774.x. Epub 2013 Jan 25.
10
The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.双膦酸盐在接受雄激素剥夺治疗的前列腺癌男性患者中的作用。
Oncology (Williston Park). 2004 May;18(5 Suppl 3):21-5.
引用本文的文献
1
Design and synthesis of polymer nanoparticles with pH-responsive pan-HDAC inhibitor (C5) derived from norbornene block copolymers to increase C5 solubility and improve its targeted delivery to prostate cancer sites.设计并合成具有pH响应性的泛组蛋白去乙酰化酶抑制剂（C5）的聚合物纳米颗粒，该抑制剂衍生自降冰片烯嵌段共聚物，以提高C5的溶解度并改善其向前列腺癌部位的靶向递送。
J Enzyme Inhib Med Chem. 2025 Dec;40(1):2530557. doi: 10.1080/14756366.2025.2530557. Epub 2025 Jul 23.
2
Potential Ophthalmological Side Effects Induced by Anti-Neoplastic Regimens for the Treatment of Genitourinary Cancers: A Review.用于治疗泌尿生殖系统癌症的抗肿瘤方案引起的潜在眼科副作用：综述
Cureus. 2022 Jul 26;14(7):e27266. doi: 10.7759/cureus.27266. eCollection 2022 Jul.
3
Prostate cancer cell proliferation is influenced by LDL-cholesterol availability and cholesteryl ester turnover.前列腺癌细胞的增殖受低密度脂蛋白胆固醇的可利用性和胆固醇酯周转的影响。
Cancer Metab. 2022 Jan 15;10(1):1. doi: 10.1186/s40170-021-00278-1.
4
Luteolin attenuates Wnt signaling via upregulation of FZD6 to suppress prostate cancer stemness revealed by comparative proteomics.木犀草素通过上调 FZD6 抑制 Wnt 信号通路从而抑制比较蛋白质组学揭示的前列腺癌干性。
Sci Rep. 2018 Jun 4;8(1):8537. doi: 10.1038/s41598-018-26761-2.
5
The use of luteinizing hormone-releasing hormone analogues is still an indispensable element of therapy in castrate-resistant prostate cancer.促黄体生成素释放激素类似物的使用仍然是去势抵抗性前列腺癌治疗中不可或缺的一部分。
Contemp Oncol (Pozn). 2014;18(2):85-9. doi: 10.5114/wo.2014.42723. Epub 2014 Jun 3.
6
Comparison of 4-hydroxynonenal-induced p53-mediated apoptosis in prostate cancer cells LNCaP and DU145.4-羟基壬烯醛诱导前列腺癌细胞LNCaP和DU145中p53介导的细胞凋亡的比较。
Contemp Oncol (Pozn). 2014;18(1):22-8. doi: 10.5114/wo.2014.40456. Epub 2014 Feb 28.
本文引用的文献
1
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.地舒单抗对比唑来膦酸治疗去势抵抗性前列腺癌骨转移患者的随机、双盲研究。
Lancet. 2011 Mar 5;377(9768):813-22. doi: 10.1016/S0140-6736(10)62344-6. Epub 2011 Feb 25.
2
A holistic approach to androgen deprivation therapy: treating the cancer without hurting the patient.
Urol Int. 2009;83(4):373-8. doi: 10.1159/000251174. Epub 2009 Dec 8.
3
Denosumab in men receiving androgen-deprivation therapy for prostate cancer.地诺单抗用于接受雄激素剥夺治疗的前列腺癌男性患者。
N Engl J Med. 2009 Aug 20;361(8):745-55. doi: 10.1056/NEJMoa0809003. Epub 2009 Aug 11.
4
Impact of androgen deprivation therapy on cardiovascular disease and diabetes.雄激素剥夺疗法对心血管疾病和糖尿病的影响。
J Clin Oncol. 2009 Jul 20;27(21):3452-8. doi: 10.1200/JCO.2008.20.0923. Epub 2009 Jun 8.
5
Quality of life and satisfaction with outcome among prostate-cancer survivors.前列腺癌幸存者的生活质量及对治疗结果的满意度
N Engl J Med. 2008 Mar 20;358(12):1250-61. doi: 10.1056/NEJMoa074311.
6
Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.前列腺癌中的雄激素剥夺疗法与动脉粥样硬化的代谢风险
J Clin Endocrinol Metab. 2008 Jun;93(6):2042-9. doi: 10.1210/jc.2007-2595. Epub 2008 Mar 18.
7
Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?雄激素剥夺疗法导致的非转移性前列腺癌男性骨折：我们究竟了解多少？
Nat Clin Pract Urol. 2008 Jan;5(1):24-34. doi: 10.1038/ncpuro0995.
8
Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis.使用钙或钙联合维生素D补充剂预防50岁及以上人群骨折和骨质流失：一项荟萃分析。
Lancet. 2007 Aug 25;370(9588):657-66. doi: 10.1016/S0140-6736(07)61342-7.
9
Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.雄激素剥夺疗法会增加前列腺癌男性患者的心血管疾病发病率。
Cancer. 2007 Oct 1;110(7):1493-500. doi: 10.1002/cncr.22933.
10
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions.前列腺癌雄激素抑制疗法对致命性心肌梗死发生频率和时间的影响。
J Clin Oncol. 2007 Jun 10;25(17):2420-5. doi: 10.1200/JCO.2006.09.3369.
Zotero 插件